NovoCure Limited (NASDAQ:NVCR) went down by -0.35% during the previous trading session, and it is maintaining the win ahead of Tuesday’s trading session. The share price of the Medical Instruments & Supplies giant went up by $62.76 to trade ended Tuesday trading at $62.98. This is down from the $62.98 price recorded on Monday’s trading session. Its performance from the start of the year has also been negative, with NVCR down by -25.53% year-to-date.
NovoCure Limited (NVCR) started the day trading at $63.43 and recorded an intraday high of $63.56. It also recorded an intraday low of $62.1 during Tuesday’s trading session. NovoCure Limited is a very active stock that recorded a trading volume that is more than 16.58% of the average daily trading volume on Tuesday. The stock’s trading volume on Tuesday was 1057224, which is more than 16.58 of the total average daily trading volume of 881.97K.
NovoCure Limited (NASDAQ:NVCR) 2020 Performance Impressive
The increase in NVCR’s stock price on Tuesday saw its overall performance boost over the past few months. We can quantify the performance of the stock so far this year using a few metrics. The 52-week high price of NVCR currently stands at $98.84, which is higher than the current trading price of the stock by 36.5%. However, NVCR’s current trading price is -17.53% lower than the 52-week low price of $53.40. In terms of trading volume, NovoCure Limited currently experienced healthy participation during the last trading session. 1057224 shares of NovoCure Limited were traded on the stock exchange on Tuesday, which is more than 16.58% of the 881.97K average trading volume of the stock.
The performance of the stock has been positive over the past year. NVCR’s performance over the past one year has seen it surge by 8.15%, while the stock has gone down by -27.87% in the last six months. The quarterly performance of NVCR currently stands at 3.02%, and it is down by -4.88% in the last month. The only negative figure was from the weekly performance, which currently reads -3.98%. At the time of writing NVCR’s report, the company has a total market cap of $6.22B, making it one of the largest publicly-traded companies in the world.NovoCure Limited also has over 782 employees all over the world.
NVCR Insider Activities
For NovoCure Limited, insiders hold 71.00% of all company shares. The insider transactions over the past six months are up by 8.00%. During that period, insiders bought 693,572 shares in 38 transactions. In that same period, insiders sold 438,821 of their shares in 34 transactions. After these transactions, insiders at NovoCure Limited now hold 16.07M shares, which is over 70.48% of the total company stocks. Institutional investors currently hold a large chunk of the NVCR shares, as they control 16.00% of the company’s total stock.
NVCR Fundamental Analysis
For NovoCure Limited, the stock’s diluted earnings per share (EPS) stands at -0.03. In the coming year, analysts expect the EPS to be 0.44. The stock’s EPS growth this year is 89.30%, 40.20% in the previous five years. In terms of revenue, NovoCure Limited’s quarterly sales (YOY) is shrinking at 0.00, which is lower than the average annual revenue of 40.20% over the past half a decade.
The Return on Investment (ROI) on NovoCure Limited’s stock currently stands at 0.20%, and it has a net profit margin of 2.30%. The operating margin of the company is 0.50%, and its gross margin is 75.40%.
NVCR Analysts Prediction
Wells Fargo reiterate their Overweight position on the stock ($85 and $90) and Evercore ISI reiterate their In-line position on the stock ($84 and $90).
Mizuho and Mizuho also believe that NovoCure Limited’s stock is outperforming at the moment. NVCR received a positive rating from Wedbush, which set a price target of $57-$80 for the stock.
At the moment, NovoCure Limited’s Total Debt to Equity ratio stands at 0.62, and they have a long-term Debt to Equity ratio of 0.62.
NVCR Technical Analysis
The Simple Moving Average (SMA) is one of the most powerful technical indicators. The 20-day Simple Moving Average of NVCR currently stands at -4.16%, while the SMA50 is -5.51%. The biggest one is the SMA200, which is currently reading -17.38% ahead of Tuesday’s trading session. The Relative Strength Index of this stock is 41.88.
